Results 1 to 10 of about 168,140 (338)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

Journal of Clinical Oncology, 2022
PURPOSE The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non–small-cell lung cancer and no disease progression after concurrent chemoradiotherapy.
D. Spigel, C. Faivre-Finn, J. Gray, D. Vicente, D. Planchard, L. Paz-Ares, J. Vansteenkiste, M. Garassino, R. Hui, X. Quantin, A. Rimner, Yi‐Long Wu, M. Özgüroğlu, K. Lee, T. Kato, M. de Wit, T. Kurata, M. Reck, B. Cho, S. Senan, J. Naidoo, H. Mann, M. Newton, P. Thiyagarajah, S. Antonia   +24 more
semanticscholar   +1 more source

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma

PLoS ONE, 2022
Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival.
Yi-Lin Chang, Ya-Fu Cheng, Hui-Shan Chen, Siao-Chi Wu, Wei-Heng Hung, Heng-Chung Chen, Chang-Lun Huang, Ching-Yuan Cheng, Bing-Yen Wang   +8 more
doaj   +2 more sources

Deficits in ascending pain modulation pathways in breast cancer survivors with chronic neuropathic pain: A resting-state fMRI study

Frontiers in Neurology, 2022
PurposeBreast cancer (BC) is the highest frequent malignancy in women globally. Approximately 25–60% of BC patients with chronic neuropathic pain (CNP) result from advances in treating BC. Since the CNP mechanism is unclear, the various treatment methods
Rui Liu, Na Qiao, Na Qiao, Shuwei Shi, Suyao Li, Yingman Wang, Jie Song, Wenting Jia   +7 more
doaj   +1 more source

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Annals of Surgery, 2023
Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. Background: Multimodality treatment improves local control in rectal cancer.
E. Dijkstra, P. Nilsson, G. Hospers, R. Bahadoer, E. Meershoek-Klein Kranenbarg, A. Roodvoets, H. Putter, A. Berglund, A. Cervantes, R. Crolla, M. Hendriks, J. Capdevila, I. Edhemovic, C. Marijnen, C. J. van de Velde, B. Glimelius, B. van Etten   +16 more
semanticscholar   +1 more source

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Journal of Clinical Oncology, 2022
PURPOSE The benefit of neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic cancer remains controversial. Initial results of the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit ...
E. Versteijne, J. V. van Dam, M. Suker, Q. Janssen, Karin B. C. Groothuis, J. M. Akkermans-Vogelaar, M. Besselink, B. Bonsing, J. Buijsen, O. Busch, G. Creemers, R. V. van Dam, F. Eskens, S. Festen, J. D. de Groot, B. Groot Koerkamp, I. D. de Hingh, M. Homs, J. V. van Hooft, E. D. Kerver, S. Luelmo, K. Neelis, J. Nuyttens, G. Paardekooper, G. Patijn, M. V. D. van der Sangen, J. de Vos-Geelen, J. Wilmink, A. Zwinderman, C. Punt, G. van Tienhoven, C. V. van Eijck   +31 more
semanticscholar   +1 more source

Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer (STELLAR)

Journal of Clinical Oncology, 2022
PURPOSE To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer.
J. Jin, Yuan Tang, Chen Hu, Liming Jiang, Jun Jiang, Ning Li, Wenyang Liu, Siyu Chen, Shuai Li, N. Lu, Yong Cai, Yongheng Li, Yuan Zhu, Guang-Hui Cheng, Hong-Yan Zhang, Xin Wang, Su-Yu Zhu, Jun Wang, Gao-Feng Li, Jialin Yang, Kuan Zhang, Y. Chi, Lin Yang, Hai-Tao Zhou, Ai-ping Zhou, S. Zou, H. Fang, Shulian Wang, Hai-zeng Zhang, Xi-shan Wang, Lichun Wei, Wenling Wang, Shi-xin Liu, Yuan-hong Gao, Ye‐Xiong Li   +34 more
semanticscholar   +1 more source

Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma

Frontiers in Genetics, 2022
Background: Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. This study aimed to distinguish patients with HCC having distinct tumour immune microenvironment (TIME) features and construct an immune-related gene signature (IRGs) to ...
Liangliang Wang, Liangliang Wang, Li Wang, Peihong He   +3 more
doaj   +1 more source

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Journal of Clinical Oncology, 2021
PURPOSE Preoperative chemoradiotherapy according to the chemoradiotherapy for esophageal cancer followed by surgery study (CROSS) has become a standard of care for patients with locally advanced resectable esophageal or junctional cancer.
B. Eyck, J. V. van Lanschot, M. Hulshof, B. J. van der Wilk, J. Shapiro, P. van Hagen, M. I. van Berge Henegouwen, B. Wijnhoven, H. V. van Laarhoven, G. Nieuwenhuijzen, G. Hospers, J. Bonenkamp, M. Cuesta, R. Blaisse, O. Busch, G. Creemers, C. Punt, J. Plukker, H. Verheul, E. S. Spillenaar Bilgen, M. V. D. van der Sangen, T. Rozema, F. T. ten Kate, J. Beukema, A. Piet, C. M. Van rij, J. Reinders, H. Tilanus, E. Steyerberg, A. van der Gaast   +29 more
semanticscholar   +1 more source

Clinical Observation of Apatinib in Treatment of Refractory Advanced Breast Cancer

Zhongliu Fangzhi Yanjiu, 2020
Objective To evaluate the clinical efficacy and safety of apatinib in the treatment of advanced breast cancer(ABC) patients refractory to multiline treatments.
WANG Jing, JIA Jinghao, LIU Jingjing, CUI Zhichao, XIONG Wei, WANG Xiaohong   +5 more
doaj   +1 more source

Identification of prognostic alternative splicing signature in gastric cancer

Archives of Public Health, 2022
Background Aberrant alternative splicing (AS) events could be viewed as prognostic indicators in a large number of malignancies. This study aims to identify prognostic AS events, illuminate the function of the splicing variants biomarkers and provide ...
Zhiwu Wang, Qiong Wu, Yankun Liu, Qingke Li, Jingwu Li   +4 more
doaj   +1 more source